+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
27 Oct 2015

Janssen’s Yondelis receives US FDA nod to treat patients with unresectable/metastatic LPS or LMS

/
Posted By
/
Comments0
/

The US Food and Drug Administration (FDA) has approved Janssen Biotech Inc’s Yondelis (trabectedin) for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.

The approval was based on recently published clinical efficacy and safety data from the phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated Yondelis versus the chemotherapy agent dacarbazine, in patients with unresectable or metastatic LPS or LMS previously treated with an anthracycline and at least one additional chemotherapy regimen.

While approved for both LPS and LMS, Yondelis is the first treatment to be specifically approved for LPS in the US.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.